Form 4: Cytosorbents Director Bator Acquires Shares and Warrants, Some Warrants Expire Unexercised
SEC Form 4 Filing
Director Michael G. Bator exercised subscription rights to acquire Cytosorbents shares and warrants, while a portion of Series A warrants expired unexercised.
Summary
- Michael G. Bator, a director of Cytosorbents Corp, filed a Form 4 detailing changes in beneficial ownership.
- On January 17, 2025, Bator exercised subscription rights from a rights offering, acquiring 15,879 shares of common stock and warrants.
- The purchase price was $1.00 per unit, totaling $15,879.
- The Series A Right Warrants exercise price was $1.13.
- Bator's holdings include 151,273 shares of common stock, including restricted stock units that vest upon a change of control.
- 5,879 Series A Warrants expired unexercised on February 24, 2025.
- Bator has granted Peter J. Mariani, Chief Financial Officer of CytoSorbents Corporation, a Limited Power of Attorney for Section 16(a) reporting obligations.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The director is increasing their stake in the company, which is generally a good sign. However, the expiration of warrants could be seen as a minor negative.
Positives
- Director's purchase of shares indicates confidence in the company.
- Exercise of subscription rights demonstrates commitment to the company's growth.
Negatives
- Expiration of warrants unexercised could indicate a lack of short-term confidence in the stock reaching a higher price.
Risks
- Dependence on a 'Change of Control' for RSU vesting may create uncertainty for the director's compensation.
Industry Context
Form 4 filings are standard practice and provide transparency into insider transactions, allowing investors to gauge management's sentiment and alignment with shareholder interests.
Comparison to Industry Standards
- Insider transactions are common across publicly traded companies, and the details disclosed in this Form 4 are consistent with regulatory requirements.
- Comparing Bator's transactions to those of other directors in similar-sized biotech companies could provide further context, but that data is not available in this document.
Stakeholder Impact
- Shareholders may view the director's increased stake as a positive signal.
- The expiration of warrants may have a negligible impact on stakeholders.
Key Dates
| Date | Description |
|---|---|
| 2016-06-07 | 60,000 RSUs granted to Bator which will vest upon a 'Change of Control' of the Company |
| 2017-02-24 | 6,000 RSUs granted to Bator which will vest upon a 'Change of Control' of the Company |
| 2018-03-15 | 3,300 RSUs granted to Bator which will vest upon a 'Change of Control' of the Company |
| 2025-01-10 | Rights Offering closed (the 'Closing Date') |
| 2025-01-17 | Reporting Person exercised certain subscription rights certificates received pursuant to a rights offering |
| 2025-02-24 | Date of transaction where Bator acquired 10,000 shares at $1.13 and Series A Warrants expired unexercised. |
| 2025-03-04 | Date of the Limited Power of Attorney execution. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.